Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cancer Diagnostic Screening Top Emerging Companies: MabCure, Radient Pharmaceuticals, Exact Sciences

|Includes: Exactech, Inc. (EXAC), RXPC

Another Cancer Diagnostic Test on my radar is MabCure, Inc., symbol (OTCPK:MBCI). I really like Cancer Diagnostic Testing stocks. They are difficult to find research on these companies and until the testing is approved they are serious cash cows, bleeding cash, and overcome by the dreaded Dilution of share price.

But once approved, this technology will increase investments ten-fold. They are highly profitable and the return on investment should be good for the companies' stocks. There is an increase in competition from new entrants and established companies. Top Tier companies include Myriad Genetics, Beckman Coulter, Roche, Siemens, Bio-Rad, and BD.

I focus on emerging testing markets currently seeking approval and MabCure fits that bill, along with Exact Sciences (NASDAQ:EXAS), who is set to disclose their clinical trial Oct. 29, and Radient Pharmaceuticals (RPC) , who has their testing approved and is currently working on sales and validation of product.

For a quick list of all companies in the market visit the following link:

Worldwide Market for Cancer Diagnostics

This article was featured in Marketwatch on MabCure's technology.

MabCure, Inc. Announces Positive Results for New Ovarian Cancer Diagnostic Blood Test
Study Results Show 94 Percent Accuracy in Confirming Diagnosis of Ovarian Cancer

Disclosure: No Position